Arkolith/Insider Trading/NRIX/Form 4

van Houte Hans

Chief Financial OfficerNurix Therapeutics, Inc. (NRIX) · full profile →Form 4 · filed Jan 30, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$61K
Net Open-Market Flow
-$61K
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 30, 2026Option exercise(M)3K—$040K
Jan 30, 2026Option exercise(M)2K—$042K
Jan 30, 2026Sell(S)73$17.37$1K45K
Jan 30, 2026Option exercise(M)3K—$049K
Jan 30, 2026Sell(S)4K$16.58$59K46K
Jan 30, 2026Option exercise(M)4K—$046K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2026Option exercise(M)4K—$019K
Jan 30, 2026Option exercise(M)3K—$00
Jan 30, 2026Option exercise(M)2K—$02K
Jan 30, 2026Option exercise(M)3K—$026K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001817217-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML